Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesReimbursement/Payment PolicyHighmark NDC Reporting Requirement Policy Update |…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ModifiedHighmark Blueshield NenyPolicy N/A

    Highmark List of Procedure Codes Requiring NDC

    Customize your policy alerts

    Sign up for all Highmark Blueshield Neny policy alerts

    Know when Highmark Blueshield Neny releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document lists HCPCS/CPT/J-codes and related procedure codes for which National Drug Code (NDC) reporting will be required effective 10/01/2025 and applies to Highmark Blueshield Neny claim submissions.

    Policy Summary
    PayerHighmark Blueshield Neny
    PolicyProcedure codes requiring NDC reporting on claims
    Policy CodePolicy N/A
    Change TypeAdded code list / billing requirement
    Effective DateOct 1, 2025
    Next Review DateN/A
    Key ActionSubmit NDC for listed procedure codes with claims beginning 10/01/2025.
    SourceLink
    POLICY UPDATE CHANGES

    A list of procedure codes requiring NDC reporting effective 10/01/2025 is provided.

    A large list of specific J- and Q- codes (HCPCS) are designated as requiring NDC reporting effective 10/01/2025.

    ~400+procedure codes listed (approx)
    10/01/2025implementation date
    20+pages with codes
    Yesincludes biosimilars/brand distinctions

    Coverage / Billing Criteria

    Billing requirement with no clinical coverage criteria in this section — lists procedure codes requiring NDC but no medical necessity criteria

    Billing requirement: The following procedure codes require National Drug Code (NDC) information to be submitted on claims when billed to Highmark Blueshield Neny effective 2025-10-01. This is an operational billing requirement only and does not convey clinical coverage or medical necessity criteria.

    Highmark List of Procedure Codes Requiring NDC Effective 10/01/2025: 90378 (RESPIRATORY SYNCYTIAL VIRUS, MONOCLONAL ANTIBODY, RECOMBINANT, FOR INTRAMUSCULAR USE, 50 MG, EACH); J1443 (INJECTION, FERRIC PYROPHOSPHATE CITRATE SOLUTION (TRIFERIC); 0.1 MG OF IRON); J2407 (INJECTION, ORITAVANCIN (ORBACTIV), 10 MG); J0690 (INJECTION, CEFAZOLIN SODIUM, 500 MG); J0692 (INJECTION, CEFEPIME HYDROCHLORIDE, 500 MG); J0696 (INJECTION, CEFTRIAXONE SODIUM, PER 250 MG); J2260 (INJECTION, MILRINONE LACTATE, 5 MG); J2405 (INJECTION, ONDANSETRON HYDROCHLORIDE, PER 1 MG); J3370 (INJECTION, VANCOMYCIN HCL, 500 MG); J7030 (INFUSION, NORMAL SALINE SOLUTION 1000 CC); J0202; J0565 (INJECTION, BEZLOTOXUMAB, 10 MG); J0604 (CINACALCET, ORAL, 1 MG, FOR ESRD ON DIALYSIS); J0606 (INJECTION, ETELCALCETIDE, 0.1 MG); J0640 (INJECTION, LEUCOVORIN CALCIUM, PER 50 MG); J0725 (INJECTION, CHORIONIC GONADOTROPIN, PER 1,000 USP UNITS); J0887 (INJECTION, EPOETIN BETA, MICROGRAM, FOR ESRD ON DIALYSIS); J0888 (INJECTION, EPOETIN BETA, MICROGRAM, FOR NON ESRD USE); J1428 (INJECTION, ETEPLIRSEN, 10 MG); J1460 (INJECTION, GAMMA GLOBULIN, INTRAMUSCULAR, 1); RITUXIMAB 10 MG AND HYALURONIDASE; J9312 (INJECTION, RITUXIMAB, 10 MG); Q2042 (TISAGENLECLEUCEL, UP TO 600 MILLION CAR-POSITIVE VIABLE T CELLS, INCLUDING LEUKAPHERESIS AND DOSE PREPARATION PROCEDURES, PER THERAPEUTIC DOSE); Q5105 (INJECTION, EPOETIN ALFA-EPBX, BIOSIMILAR, (RETACRIT) (FOR ESRD ON DIALYSIS), 100 UNITS); Q5106 (INJECTION, EPOETIN ALFA-EPBX, BIOSIMILAR, (RETACRIT) (FOR NON-ESRD USE), 1000 UNITS); Q5107 (INJECTION, BEVACIZUMAB-AWWB, BIOSIMILAR, (MVASI), 10 MG); Q5109 (INJECTION, INFLIXIMAB-QBTX, BIOSIMILAR, (IXIFI), 10 MG); Q9991 (INJECTION, BUPRENORPHINE EXTENDED-RELEASE (SUBLOCADE), <= 100 MG); Q9992 (INJECTION, BUPRENORPHINE EXTENDED-RELEASE (SUBLOCADE), > 100 MG); J0179 (INJECTION, BROLUCIZUMAB-DBLL, 1 MG); J9309 (INJECTION, POLATUZUMAB VEDOTIN-PIIQ, 1 MG); J9199 (INJECTION, GEMCITABINE HYDROCHLORIDE (INFUGEM), 200 MG); J0693 (INJECTION, CEFIDEROCOL, 5 MG); J1823 (INJECTION, INEBILIZUMAB-CDON, 1 MG); J7212 (FACTOR VIIA (ANTIHEMOPHILIC FACTOR, RECOMBINANT)-JNCW (SEVENFACT), 1 MICROGRAM); J7352; J0216 (INJECTION, ALFENTANIL HYDROCHLORIDE, 500 MICROGRAMS); J0457 (INJECTION, AZTREONAM, 100 MG); J0665 (INJECTION, BUPIVICAINE, NOT OTHERWISE SPECIFIED, 0.5 MG); J0736 (INJECTION, CLINDAMYCIN PHOSPHATE, 300 MG); J0737 (INJECTION, CLINDAMYCIN PHOSPHATE (BAXTER); NOT THERAPEUTICALLY EQUIVALENT TO J0736, 300 MG); J1440 (FECAL MICROBIOTA, LIVE JSLM, 1 ML); J1576 (INJECTION, IMMUNE GLOBULIN (PANZYGA); INTRAVENOUS, NON-LYOPHILIZED, 500 MG); J1805 (INJECTION, ESMOLOL HYDROCHLORIDE, 10 MG); J1811 (INSULIN (FIASP) FOR ADMINISTRATION THROUGH DME PER 50 UNITS); J1812 (INSULIN (FIASP); PER 5 UNITS); J1813 (INSULIN (LYUMJEV) FOR ADMINISTRATION THROUGH DME PER 50 UNITS); J1814 (INSULIN (LYUMJEV), PER 5 UNITS); J1836 (INJECTION, METRONIDAZOLE, 10 MG); J1920 (INJECTION, LABETALOL HYDROCHLORIDE, 5 MG); J1941 (INJECTION, FUROSEMIDE (FUROSCIX), 20 MG); J2249 (INJECTION, REMIMAZOLAM, 1 MG); J2305 (INJECTION, NITROGLYCERIN, 5 MG); J2329 (INJECTION, UBLITUXIMAB-XIIY); J7321 (HYALURONAN OR DERIVATIVE, HYALGAN, SUPARTZ OR VISCO-3, FOR INTRA-ARTICULAR INJECTION, PER DOSE); J0224 (INJECTION, LUMASIRAN, 0.5 MG); J1951 (INJECTION, LEUPROLIDE ACETATE FOR DEPOT SUSPENSION (FENSOLVI), 0.25 MG); J7168 (PROTHROMBIN COMPLEX CONCENTRATE (HUMAN); KCENTRA, PER I.U. OF FACTOR IX ACTIVITY); J9348 (INJECTION, NAXITAMAB-GQGK, 1 MG); J9353 (INJECTION, MARGETUXIMAB-CMKB, 5 MG); Q5123 (INJECTION, RITUXIMAB-ARRX, BIOSIMILAR, (RIABNI); 10 MG); J0138 (INJECTION, ACETAMINOPHEN 10 MG AND IBUPROFEN 3 MG); J0175 (INJECTION, DONANEMAB-AZBT, 2 MG); J1171 (INJECTION, HYDROMORPHONE, 0.1 MG); J1749 (INJECTION, ILOPROST, 0.1 MCG); J2002 (INJECTION, LIDOCAINE HCL IN 5% DEXTROSE, 1 MG); J2003 (INJECTION, LIDOCAINE HYDROCHLORIDE, 1 MG); J2004; J2252 (INJECTION, MIDAZOLAM IN 0.8% SODIUM CHLORIDE, INTRAVENOUS, NOT THERAPEUTICALLY EQUIVALENT TO J2250, 1 MG); J2253 (INJECTION, MIDAZOLAM (SEIZALAM), 1 MG); J2601 (INJECTION, VASOPRESSIN (BAXTER), 1 UNIT); J8522 (CAPECITABINE, ORAL, 50 MG); J8541 (DEXAMETHASONE (HEMADY), ORAL, 0.25 MG); J9329 (INJECTION, TISLELIZUMAB-JSGR, 1 MG); Q5135 (INJECTION, TOCILIZUMAB-AAZG (TYENNE), BIOSIMILAR, 1 MG); Q5136 (INJECTION, DENOSUMAB-BBDZ (JUBBONTI/WYOST), BIOSIMILAR, 1 MG); J0121 (INJECTION, OMADACYCLINE, 1 MG); J0122 (INJECTION, ERAVACYCLINE, 1 MG); J0222 (INJECTION, PATISIRAN, 0.1 MG); J0291 (INJECTION, PLAZOMICIN, 5 MG); J0593 (INJECTION, LANADELUMAB-FLYO, 1 MG); J1096 (DEXAMETHASONE, LACRIMAL OPHTHALMIC INSERT, 0.1 MG); J1097 (PHENYLEPHRINE 10.16 MG/ML AND KETOROLAC 2.88 MG/ML OPHTHALMIC IRRIGATION SOLUTION, 1 ML); J1303 (INJECTION, RAVULIZUMAB-CWVZ, 10 MG); J1943 (INJECTION, ARIPIPRAZOLE LAUROXIL, (ARISTADA INITIO), 1 MG); J1944 (INJECTION, ARIPIPRAZOLE LAUROXIL, (ARISTADA), 1 MG); J2798 (INJECTION, RISPERIDONE, (PERSERIS), 0.5 MG); J1650 (INJECTION, ENOXAPARIN SODIUM, 10 MG); J1652 (INJECTION, FONDAPARINUX SODIUM, 0.5 MG); J1670 (INJECTION, TETANUS IMMUNE GLOBULIN, HUMAN, UP TO 250 UNITS); J1700 (INJECTION, HYDROCORTISONE ACETATE, UP TO 25 MG); J1720 (INJECTION, HYDROCORTISONE SODIUM SUCCINATE, UP TO 100 MG); J1726 (INJECTION, HYDROXYPROGESTERONE CAPROATE, (MAKENA), 10 MG); J1729 (INJECTION, HYDROXYPROGESTERONE CAPROATE, NOT OTHERWISE SPECIFIED, 10 MG); J1740 (INJECTION, IBANDRONATE SODIUM, 1 MG); J1741 (INJECTION, IBUPROFEN, 100 MG); J1742 (INJECTION, IBUTILIDE FUMARATE, 1 MG); J1743 (INJECTION, IDURSULFASE, 1 MG); J1744 (INJECTION, ICATIBANT, 1 MG); J1745 (INJECTION, INFLIXIMAB, 10 MG); J1750 (INJECTION, IRON DEXTRAN, 50 MG); J1756 (INJECTION, IRON SUCROSE, 1 MG); J1786 (INJECTION, IMIGLUCERASE, 10 UNITS); J1790 (INJECTION, DROPERIDOL, UP TO 5 MG); J1800 (INJECTION, PROPRANOLOL HCL, UP TO 1 MG); J1815 (INJECTION, INSULIN, PER 5 UNITS); J1817 (INSULIN FOR ADMINISTRATION THROUGH DME PER 50 UNITS); J1826 (INJECTION, INTERFERON).
    Policy Summary
    PayerHighmark Blueshield Neny
    PolicyProcedure codes requiring NDC reporting on claims
    Policy CodePolicy N/A
    Change TypeAdded code list / billing requirement
    Effective DateOct 1, 2025
    Next Review DateN/A
    Key ActionSubmit NDC for listed procedure codes with claims beginning 10/01/2025.
    SourceLink
    On This Page
    Coverage / Billing CriteriaAffected Procedure Codes & Effective DateProvider Billing Actions RequiredDefinitions & Scope
    title

    Codes requiring NDC

    Codes requiring NDC submission when billed (consolidated list): 90378, J1443, J2407, J0690, J0692, J0696, J2260, J2405, J3370, J7030, J0202, J0565, J0604, J0606, J0640, J0725, J0887, J0888, J1428, J1460, J9312, Q2042, Q5105, Q5106, Q5107, Q5109, Q9991, Q9992, J0179, J9309, J9199, J0693, J1823, J7212, J7352, J0216, J0457, J0665, J0736, J0737, J1440, J1576, J1805, J1811, J1812, J1813, J1814, J1836, J1920, J1941, J2249, J2305, J2329, J7321, J0224, J1951, J7168, J9348, J9353, Q5123, J0138, J0175, J1171, J1749, J2002, J2003, J2004, J2252, J2253, J2601, J8522, J8541, J9329, Q5135, Q5136, J0121, J0122, J0222, J0291, J0593, J1096, J1097, J1303, J1943, J1944, J2798, J1650, J1652, J1670, J1700, J1720, J1726, J1729, J1740, J1741, J1742, J1743, J1744, J1745, J1750, J1756, J1786, J1790, J1800, J1815, J1817, J1826

    Affected Procedure Codes & Effective Date

    Example listed codes requiring NDCHCPCSCovered
    J1443INJECTION, FERRIC PYROPHOSPHATE CITRATE SOLUTION (TRIFERIC)
    J1555INJECTION, IMMUNE GLOBULIN (CUVITRU)
    Q5101INJECTION, FILGRASTIM-SNDZ (ZARXIO), BIOSIMILAR
    Sample listed HCPCS/J-codes requiring NDCHCPCS
    J9312INJECTION, RITUXIMAB, 10 MG
    Q2042TISAGENLECLEUCEL, up to 600 million CAR-positive viable T cells, per therapeutic dose
    J9316INJECTION, PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF, per 10 mg
    Examples from listHCPCS
    J7321HYALURONAN OR DERIVATIVE, HYALGAN, SUPARTZ OR VISCO-3, FOR INTRA-ARTICULAR INJECTION, PER DOSE
    J0224INJECTION, LUMASIRAN, 0.5 MG
    J1951INJECTION, LEUPROLIDE ACETATE FOR DEPOT SUSPENSION (FENSOLVI), 0.25 MG
    J7168PROTHROMBIN COMPLEX CONCENTRATE (HUMAN); KCENTRA, PER I.U. OF FACTOR IX ACTIVITY
    sample codes from listHCPCS
    J1650INJECTION, ENOXAPARIN SODIUM, 10 MG.
    J1745INJECTION INFLIXIMAB, 10 MG.
    J2997INJECTION, ALTEPLASE RECOMBINANT, 1 MG.
    J9035INJECTION, BEVACIZUMAB 10 MG.
    Q0138INJECTION, FERUMOXYTOL, 1 MG.
    S0136CLOZAPINE, 25 MG.
    S5550INSULIN, RAPID ONSET; 5 UNITS.
    inv-09: Effective date — policy implementation date
    Effective date10/01/2025
    Policy applicabilityApplies to Highmark BlueShield NENY claim submissions for listed procedure codes
    ScopeBilling requirement only — NDC must be reported on claims for listed procedure codes

    Provider Billing Actions Required

    Billing Rule

    NDC Submission Required

    Providers must submit the National Drug Code (NDC) on claims for the procedure codes listed by Highmark below. This requirement applies to claims with dates of service on or after 2025-10-01. Failure to include the appropriate NDC may result in claim rejection or delay in payment.

    • Effective date: 2025-10-01
    • Requirement: Submit NDC on the claim for each applicable line item
    Documentation Required

    NDC Reporting Requirement

    For the procedure codes listed by Highmark, providers must report the corresponding NDC value on all submitted claims (professional and facility). Ensure the NDC is formatted and placed in the NDC field per payer/billing system specifications and that units and quantity align with the billed HCPCS/J-code.

    • Applies to: All providers billing the listed procedure codes
    • Claims affected: Professional (CMS-1500/837P) and Institutional (UB-04/837I) claims
    Note

    Highmark Procedure Codes Requiring NDC

    Highmark’s list of procedure codes requiring NDC submission (effective 10/01/2025) includes, but may not be limited to, the following HCPCS/CPT/J/Q codes. Providers must include the NDC for these codes when filing claims on or after the effective date: 90378, J1443, J2407, J0690, J0692, J0696, J2260, J2405, J3370, J7030, J0202, J0565, J0604, J0606, J0640, J0725, J0887, J0888, J1428, J1460, J9312, Q2042, Q5105, Q5106, Q5107, Q5109, Q9991, Q9992, J0179, J9309, J9199, J0693, J1823, J7212, J7352, J7321, J0224, J1951, J7168, J9348, J9353, Q5123, J0138, J0175, J1171, J1749, J2002, J2003, J2004, J2252, J2253, J2601, J8522, J8541, J1650, J1652, J1670, J1700, J1720, J1726, J1729, J1740, J1741, J1742, J1743, J1744, J1745, J1750, J1756, J1786, J1790, J1800, J1815, J1817, J1826.

    • List type: Highmark procedure codes requiring NDC
    • Effective date: 2025-10-01
    • Action: Include NDC and units on claim line for each listed code
    Documentation Required

    Operational Guidance and Documentation

    Operational notes: 1) If a billed code is on the Highmark list, include the product NDC (11-digit) and unit quantity corresponding to the paid amount. 2) For combination products or biosimilars, submit the specific product NDC actually administered. 3) Maintain documentation linking the NDC to the administered drug in the medical record in case of audit. 4) For questions about code applicability or NDC placement, contact Highmark provider services.

    • NDC format: 11-digit (NPI-compatible billing systems may require zero-padding)
    • Documentation: Retain records tying NDC to administration for audit

    Definitions & Scope

    inv-14: Procedure codes requiring NDC — definition listing which procedure codes require NDC reporting
    Code types includedHCPCS procedure codes (examples include J-, Q-, S- and miscellaneous codes) listed throughout the document
    Example codes (sample)J1443, J2407, Q5101 (see full list in document)
    List sizeExtensive enumerated list spanning many chunks (approx. 400+ codes across document)
    inv-15: National Drug Code (NDC) must be submitted with claims for the listed procedure codes — definition of requirement
    Requirement summaryNational Drug Code (NDC) must be submitted with claims for each listed procedure code effective 10/01/2025
    Provider actionInclude NDC information on claim lines when billing any procedure code enumerated in the Highmark list
    Nature of requirementOperational/billing requirement — not clinical coverage criteria
    inv-16: NDC requirement — short definition/statement of reporting requirement
    Short statementNDC reporting is required on claims for the enumerated procedure codes effective 10/01/2025
    Applies toAll claim lines using the HCPCS/CPT/J/Q/S codes listed in the document
    Enforcement dateEffective 10/01/2025 (operational requirement)
    inv-17: Procedure codes requiring NDC — list includes HCPCS J-, Q-, S- and miscellaneous codes for which NDC is required
    Included code seriesJ- codes, Q- codes, S- codes and miscellaneous HCPCS entries are included in the list
    Representative HCPCS J-codesJ1650, J1745, J9035, J9312 (among many others listed)
    Representative Q- and S-codesQ5105, Q5123, Q5109, S0136, S5550 (examples from list)
    Document examplesSee chunks with enumerated entries: chunk 0, chunk 18, chunk 36, chunk 54 for full code listings